Searchable abstracts of presentations at key conferences in endocrinology

ea0049gp184 | Pituitary | ECE2017

Hormonal and metabolic effects of long-term cabergoline withdrawal in patients with hyperprolactinemia

Auriemma Renata Simona , Blasio Chiara , Grasso Ludovica Francesca Stella , Galdiero Mariano , Negri Mariarosaria , Pivonello Claudia , Granieri Luciana , Colao Annamaria , Pivonello Rosario

Hyperprolactinemia is associated with abnormalities in glucose and lipid profile with development of insulin resistance and metabolic syndrome (MetS), which have been found to be improved by treatment with cabergoline (CAB). The current study aimed at investigating hormonal and metabolic effects of long-term CAB withdrawal in patients with prolactinomas. In 46 patients (37 F, 9 M, aged 34.5±11.5 yrs, 36 microadenomas and 10 macroadenomas) anthropometric (weight, BMI, wais...

ea0020p196 | Endocrine tumours and neoplasia | ECE2009

Safety of long-term combined therapy with somatostatin analogues and cabergoline (CAB) on cardiac valve in acromegaly: an echocardiography study

Auriemma Renata Simona , Galderisi Maurizio , Galdiero Mariano , Grasso Ludovica Francesca Stella , De Martino Maria Cristina , De Leo Monica , Colao Annamaria , Pivonello Rosario

The aim of the present study was to evaluate cardiac valve insufficiency prevalence after 12-month combined treatment with somatostatin analogues (SA) and CAB in acromegalic patients partially responsive to high-dose and long-term SA monotherapy. Twenty-four patients entered the study. A standard echocardiography was performed in all patients at diagnosis, after high-dose and long-term SA therapy and 12 months after CAB addition to SA to evaluate ejection fraction (EF) and mit...